{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:06:36Z","timestamp":1792821996421,"version":"4.5.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Tokyo Women\u2019s Medical University"},{"name":"Ayumi Pharmaceutical Co."},{"name":"Bristol Myers Squib"},{"name":"Chugai Pharmaceutical Co., Ltd"},{"name":"Eisai Co., Ltd"},{"name":"Nippon Kayaku Co., Ltd"},{"name":"Taisho Toyama Pharmaceutical Co., Ltd"},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mitsubishi Tanabe Pharma Co."},{"name":"Teijin Pharma Ltd"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Abbvie Japan Co., Ltd"},{"name":"Bristol-Myers Squibb K.K."},{"name":"Chugai Pharmaceutical Co., Ltd"},{"name":"Eisai Co., Ltd"},{"name":"Mitsubishi Tanabe Pharma Co."},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taisho Toyama Pharmaceutical Co., Ltd"},{"name":"Santen Pharmaceutical Co., Ltd"},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Teijin Pharma, Ltd"},{"name":"Pfizer Japan Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/rheumatology\/key287","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T11:14:08Z","timestamp":1536578048000},"page":"i34-i42","source":"Crossref","is-referenced-by-count":209,"title":["Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"58","author":[{"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Pharmacoepidemiology, Department of Rheumatology, School of Medicine, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"key\n\t\t\t\t2019022610403570100_key287-B1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B4","first-page":"Abstract 1647","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years (Abstract 1647)","volume":"69","author":"Wollenhaupt","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/annrheumdis-2017-eular.1325","article-title":"Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis (FRI0090)","volume":"76","author":"Kremer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2017-eular.1335","article-title":"Effects of baricitinib on haemoglobin and related laboratory parameters in rheumatoid arthritis patients (FRI0092","volume":"76","author":"Kay","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B7","first-page":"S357","article-title":"Characterization of changes in lymphocyte (LYM) subsets in baricitinib (Bari)-treated patients (pts) with rheumatoid arthritis (RA) in a phase 3 study (RA-BEAM","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B8","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar4673","article-title":"Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials","volume":"16","author":"Isaacs","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B9","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B10","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/art.34530","article-title":"Development and validation of a risk score for serious infection in patients with rheumatoid arthritis","volume":"64","author":"Crowson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B11","doi-asserted-by":"crossref","first-page":"e000498","DOI":"10.1136\/rmdopen-2017-000498","article-title":"Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme","volume":"3","author":"Yamanaka","year":"2017","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/annrheumdis-2017-eular.1312","article-title":"Serious infection and associated risk factors in patients with moderate to severe rheumatoid arthritis treated with baricitinib (OP0248","volume":"76","author":"Winthrop","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B14","first-page":"S98","article-title":"Herpes zoster in patients including Japanese with moderate to severe active rheumatoid arthritis treated with baricitinib, an oral JAK 1\/JAK 2 inhibitor (Abstract W13-6","volume":"27","author":"Atsumi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B15","first-page":"Abstract 511","article-title":"Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysis (Abstract #511","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B16","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208105","article-title":"How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries","volume":"75","author":"Askling","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B19","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/rmdopen-2017-000491","article-title":"Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B20","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B21","article-title":"Post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data (Abstract 431)","volume":"69(Suppl 10)","author":"Mimori","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B23","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B24","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard.2005.047274","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan","volume":"65","author":"Yamada","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B26","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1756-185X.12539","article-title":"Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan","volume":"17(Suppl 3)","author":"Chiu","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B29","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.5588\/ijtld.13.0368","article-title":"Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan","volume":"17","author":"Ke","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B30","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B32","first-page":"S97","article-title":"Long-term safety of baricitinib, an oral JAK1\/JAK2 inhibitor, in patients with moderate to severe active rheumatoid arthritis: an integrated analysis (Abstract W13-1","volume":"27","author":"Harigai","year":"2017","journal-title":"Mod Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B33","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B34","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B36","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B37","article-title":"Potential opportunistic infections, and other infections of interest in patients with moderate to severe rheumatoid arthritis in the baricitinib program (Abstract 2787","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13075-014-0449-5","article-title":"The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study","volume":"16","author":"Wu","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B43","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B44","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.3892\/ol.2017.6473","article-title":"A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer","volume":"14","author":"Shimaoka","year":"2017","journal-title":"Oncol Lett"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/acr.23421","article-title":"Lymphoma in the tofacitinib rheumatoid arthritis clinical development program","volume":"70","author":"Mariette","year":"2018","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","article-title":"Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis","volume":"47","author":"Maneiro","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B47","article-title":"Thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs (Abstract 16L","author":"Mease","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-014-2492-7","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"33","author":"Ungprasert","year":"2014","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B50","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B53","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B54"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B55"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B56","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/kep052","article-title":"Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sawada","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B57","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/rheumatology\/kep227","article-title":"Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sato","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/annrheumdis-2012-201944","article-title":"Rheumatoid_Arthritis_Interstitial_Lung_Disease_Study_Consortium. HLA-A*31: 01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker?","volume":"72","author":"Furukawa","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B59","year":"2018"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B60","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B61","volume-title":"Summary of Product Characteristics, Olumiant 2 mg and 4 mg Film-coated Tablets","year":"2018"},{"key":"key\n\t\t\t\t2019022610403570100_key287-B62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/Supplement_1\/i34\/27984869\/key287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:28:00Z","timestamp":1751851680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/Supplement_1\/i34\/5365418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":62,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key287","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}